- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00271284
Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients (VARIABILITE)
A Crossover, Multicentre, Randomised Trial Comparing the Effect on the Control of Blood Glucose Concentration of Insulin Glargine and Insulin Detemir, Combined With Insulin Glulisine, Used as a Bolus, in Type 1 Diabetic Patients
·Main objective: To compare the variability of fasting capillary blood glucose concentration, observed with insulin glargine combined with insulin glulisine and with insulin detemir combined with insulin glulisine, in type 1 diabetics. It is a non-inferiority study.
·Secondary objectives:
Efficacy:
- To compare the variability of blood glucose concentration before the evening meal, observed with insulin glargine combined with insulin glulisine and with insulin detemir combined with insulin glulisine, in type 1 diabetics.
- To record the intra- and inter-daily variability using the MAGE and MODD indices [1,2,3,4]
- To compare the glycaemic profiles (7 points)
- To evaluate the HbA1c concentration, at the end of each period of treatment, weight change, the dose of insulin used and the number of daily injections.
Tolerance:
- To record undesirable events
- To evaluate the safety in use from the record of episodes of hypoglycaemia (symptomatic, diurnal, nocturnal, severe).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria :
- Belonging to a social security scheme or covered by such a scheme
- With type 1 diabetes (defined as a concentration of C-peptide < 0.1 nmol//l and a fasting blood glucose of >= 1.26 g/l), diagnosed not less than 5 years previously
- Treated for at least 6 months by intensive insulin treatment, following a basal-bolus system, using insulin glargine (Lantus®) as basal insulin. During the study, this insulin will administered in the evening
- Trained in the titration of prandial insulin (the dose of rapid insulin decided at each mealtime depending on the composition of the meal)
- With an HbA1c level of <= 8.5% at the inclusion visit
- Capable of checking their blood glucose concentration using the material supplied by the sponsor: blood glucose meter and patient notebook
- Able to eat 3 regular daily meals on the days for recording the blood glucose cycle and similarly as much as possible on other days throughout the length of the study
- Able to continue their usual daily activities during the study
- Women of child-bearing potential should be using an effective method of contraception
- Fundal examination result less than a year old available
Exclusion Criteria:
- Recent history of severe hypoglycaemia (at least 2 events in the 6 months prior to inclusion)
- An episode of acidocetosis in the 3 months prior to inclusion
- Proliferating retinopathy, defined as having required treatment by surgery or photocoagulation, in the 6 months prior to visit 1, or non-stabilised (rapidly developing) retinopathy which may require photocoagulation or surgery
- Pancreatectomy
- Altered hepatic function (AST or ALT >= 2.5 x normal, in the initial measurements)
- Altered renal function (plasma creatinine > 1.5 mg/dl)
- Acute infection
- Acute or chronic metabolic acidosis
- Gastroparesis
- History of cancer in the last 5 years
- Medically significant cardiovascular, hepatic, neurological or endocrine disease or any other significant disease making carrying out the protocol or interpreting the trial results difficult
- History of drug or alcohol abuse
- Subject likely to receive treatment during the trial which is not authorised in the protocol (see Section 6.2), in particular, treatment by corticosteroids whatever the route of administration or dose.
- Antidiabetic treatment by products other than those supplied within the framework of this study
- Treatment by another product undergoing development during the 3 months prior to inclusion in the trial
- Hypersensitivity to one of the study products (insulin glargine, insulin detemir, insulin glulisine) or to one of the excipients present in the insulin preparations, used in the study
- Working at night
- Pregnancy
- Breast-feeding
- Mental state making the subject incapable of understanding the objectives and possible consequences of the trial
- Subject unable to submit to the restrictions of the protocol (e.g. uncooperative, incapable of attending monitoring visits and probably incapable of finishing the trial)
- Subject deprived of his liberty because of an administrative or legal decision
- The investigator or any member of the team or close to the investigator directly implicated in the trial particularly assistant doctors, pharmacists, nurses, trial coordinator, etc.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I
|
insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
|
Active Comparator: II
|
insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy data : fasting blood glucose concentration
Time Frame: read daily during the last 2 months of each period
|
read daily during the last 2 months of each period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tolerance data : undesirable events including episodes of hypoglycaemia
Time Frame: throughout the study
|
throughout the study
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Marie SEBILLE, Dr, Sanofi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HMR1964A_3516
- EudraCT #: 2005-002771-32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on insulin glulisine / insulin glargine
-
SanofiTerminatedDiabetes Mellitus, Type 2Brazil
-
SanofiCompletedDiabetes Mellitus, Type 2United States
-
SanofiCompletedDiabetes Mellitus, Type 1Bahrain, Kuwait, Qatar, United Arab Emirates
-
SanofiCompleted
-
HaEmek Medical Center, IsraelCompletedDiabetes Mellitus Type 2
-
SanofiCompleted
-
SanofiCompletedDiabetes Mellitus, Type 2Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
-
SanofiCompletedDiabetes Mellitus, Type 1Belarus
-
SanofiCompletedInsulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal InsulinDiabetes Mellitus, Type 2United States